

PE/Fire™ 640 anti-human CD45RO

Catalog # / Size:	2121320 / 100 tests 2121315 / 25 tests	□ Human peripheral blood lymphocytes were stained with CD45RA FITC and CD45RO (clone UCHL1) PE/Fire™ 640 (left), or CD45RA FITC only (right).
Clone:	UCHL1	
Isotype:	Mouse IgG2a, κ	
Immunogen:	IL-2 dependent T cell line, CA1	
Reactivity:	Human, Non-human primate, Other	
Preparation:	The antibody was purified by affinity chromatography and conjugated with PE/Fire™ 640 under optimal conditions.	
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)	
Workshop Number:	IV N31	
Concentration:	Lot-specific	□

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PE/Fire™ 640 has a maximum excitation of 566 nm and a maximum emission of 639 nm.

Application Notes: The UCHL1 antibody is commonly used in combination with antibodies against CD45RA to discern memory and naïve T cells. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections⁵ and formalin-fixed paraffin-embedded tissue sections⁴, Western blotting², and immunoprecipitation³.

**Application
References:**

1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. (FC)
 2. Ishii T, et al. 2001. *P. Natl. Acad. Sci. USA* 98:12138. (WB)
 3. Ponsford M, et al. 2001. *Clin. Exp. Immunol.* 124:315. (IP)
 4. Yamada M, et al. 1996. *Stroke* 27:1155. (IHC)
 5. Sakkas LI, et al. 1998. *Clin. Diagn. Lab. Immunol.* 5:430. (IHC)
 6. Baba N, et al. 2010. *Int. Immunol.* 22:237. [PubMed](#)
 7. Thakral D, et al. 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
 8. Weiss L, et al. 2010. *P. Natl. Acad. Sci. USA* 107:10632. [PubMed](#)
 9. Wu YY, et al. 2007. *Infect. Immun.* 75:4357. [PubMed](#)
 10. Mozaffarian N, et al. 2008. *Rheumatology* 47:1335. [PubMed](#)
 11. Roque S, et al. 2007. *J. Immunol.* 178:8028. [PubMed](#)
 12. Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
 13. Smith SH, et al. 1986. *Immunology* 58:63. (Immunogen)
 14. Peterson VM, et al. 2017. *Nat. Biotechnol.* 35:936. (PG)
-

Description: CD45RO is a 180 kD single chain membrane glycoprotein. It is a splice variant of tyrosine phosphatase CD45, lacking the A, B, and C determinants. The CD45RO isoform is expressed on activated and memory T cells, some B cell subsets, activated monocytes/macrophages, and granulocytes. CD45RO enhances both T cell receptor and B cell receptor signaling mediated activation. CD45 and its isoforms non-covalently associate with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1 and CD22. CD45 isoform expression can change in response to cytokines.

- Antigen
References:**
1. Thomas M. 1989. *Annu. Rev. Immunol.* 7:339.
 2. Trowbridge I, et al. 1994. *Annu. Rev. Immunol.* 12:85.